Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

upjohn (malaysia) sdn. bhd. - phenytoin sodium -

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company - cortisone acetate (unii: 883wkn7w8x) (cortisone - unii:v27w9254fz) - tablet - 5 mg - - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) - congenital adrenal hyperplasia - hypercalcemia associated with cancer - nonsuppurative thyroiditis as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - psoriatic arthritis - rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) - ankylosing spondylitis - post-traumatic osteoarthritis - acute and subacute bursitis - synovitis of osteoarthritis - acute nonspecific tenosynovitis - epicondylitis - acute gouty arthritis during an exacerbation or as maintenance therapy in selected cases of: - systemic lupus erythematosus - acute rheumatic carditis - systemic dermatomyositis (polymyositis) - pemphigus - exfoliative dermatitis -

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company llc - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - alprostadil 500 ug in 1 ml - prostin vr pediatric sterile solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. in infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment po2 values; that is, patients with low po2 values respond best, and patients with po2 values of 40 torr or more usually have little response. prostin vr pediatric should be administered only by trained personnel in facilities that provide pediatric intensive care. none.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - heparin sodium 10 iu/ml;   - solution for injection - 50 iu/5ml - active: heparin sodium 10 iu/ml   excipient: sodium chloride water for injection

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company llc - pegvisomant (unii: n824aou5xv) (pegvisomant - unii:n824aou5xv) - pegvisomant 10 mg in 1 ml - somavert is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. the goal of treatment is to normalize serum insulin-like growth factor-i (igf-i) levels. none. risk summary the limited data with somavert in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in animal reproduction studies, fetotoxicity was observed at a dose that was 6 times the maximum recommended human dose based on body surface area following subcutaneous administration of pegvisomant during organogenesis or during the preimplantation period (see data ). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. data animal data the effects of pegviso

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn and company - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - tablet - 2.5 mg - deltasone tablets are indicated in the following conditions: systemic fungal infections and known hypersensitivity to components.

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company - hydrocortisone cypionate (unii: 4xdy25l70b) (hydrocortisone - unii:wi4x0x7bpj) - 10 mg in 5 ml

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company llc - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 40 mg in 1 ml

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company - tolazamide (unii: 9lt1bro48q) (tolazamide - unii:9lt1bro48q) - tablet - 100 mg - tolinase tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin dependent diabetes mellitus (type ii) whose hyperglycemia cannot be satisfactorily controlled by diet alone. in initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. the importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. use of tolinase must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restra

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company - estropipate (unii: svi38uy019) (estropipate - unii:svi38uy019) - cream - 1.5 mg in 1 g - ogen vaginal cream is indicated for the treatment of vulval and vaginal atrophy. estrogens should not be used in individuals with any of the following conditions: - known or suspected pregnancy (see boxed warning ). estrogens may cause fetal harm when administered to a pregnant woman. - undiagnosed abnormal genital bleeding. - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - active thrombophlebitis or thromboembolic disorders. ogen vaginal cream (estropipate) is contraindicated in patients hypersensitive to its ingredients.